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Abstract: Of several newer delivery systems under development and investigation for the 
administration of opioids, the intranasal route has received a substantial amount of attention. 
Intranasal administration is a convenient form of delivery that is applicable to several opioids. 
It has the potential for self-administration, combined with a rapid onset of action, allowing for 
patient-controlled analgesia. In clinical practice, intranasal administration has been found to be 
a reliable drug delivery method that is familiar to patients. Intranasal opioids have proven to 
be useful in both in-hospital and out-of-hospital pain management settings. Fentanyl, a highly 
lipophilic step 3 opioid, has been evaluated for intranasal administration. The purpose of this 
review is to examine the role of the nasal route of opioid administration and examine the evidence 
base for the use of fentanyl intranasally.
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Introduction
Pain is a common symptom in the general population and has a substantial impact on 
quality of life. Pain can be a major burden to patients and society. Opioids are among 
the most potent analgesics available and are the cornerstone of treatment for moderate 
to severe pain associated with cancer.1 Opioids can decrease pain and improve function.2 
Most commonly recommended is the oral route of administration. There are times when 
nonoral routes of administration are necessary, such as in patients with advanced illness 
or in the postoperative period. Nonoral routes of administration have been shown to 
be more effective than the oral route by providing enhanced absorption and avoidance 
of first-pass effects. The nonoral routes of opioid administration include parenteral 
(subcutaneous, intravenous), rectal, sublingual, and transmucosal. The parenteral routes 
of administration are associated with rapid onset of action but can be associated with 
pain and inconvenience. The rectal route of administration has been evaluated for opioid 
administration and, although effective, can have limitations in terms of dignity for the 
patient and lack of uniform absorption. The sublingual and transmucosal routes are 
effective nonoral routes that have the advantage of avoiding presystemic elimination, 
yet can have suboptimal absorption due to swallowing. Lack of salivary production 
may impede the absorption of opioids when given by the transmucosal route.
The intranasal route has increasingly been viewed as a new alternative route for 
drug administration. The intranasal route is a convenient form of delivery that is 
applicable to several opioids and has the potential for self-administration, combined 
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found to be a reliable drug delivery method that is familiar to 
patients. Intranasal opioids have proven to be useful in both 
in-hospital and out-of-hospital pain management settings. 
Fentanyl (Figure 1) is a step 3 opioid that is used for acute and 
chronic pain of both malignant and nonmalignant origin. It is 
a lipophilic, short-acting, synthetic opioid with a piperidine 
chemical structure.3 Fentanyl can be administered by the 
transdermal, transmucosal, or sublingual routes, in addition 
to the traditional parenteral routes. Recently, fentanyl has 
been evaluated for intranasal administration. The purpose of 
this review is to examine the role of the nasal route of opioid 
administration and examine the evidence base for the use of 
fentanyl intranasally.
Anatomy and physiology of the nose
In adults, the nasal mucosa provides a large mucosal surface 
area (150–180 cm2) that is closely associated with high blood 
flow.4 This blood flow is greater per cubic centimeter of 
tissue than that of muscle, the brain, or the liver.4 The nose 
has a direct connection to the central nervous system via the 
olfactory route. Theoretically, the direct delivery of drugs 
to the brain allows lower doses of drugs to be used, with 
less delivery to nontargeted organs, and perhaps less toxic 
side effects.5 The nasal mucosa has a pH of 5.5–6.5, which 
maintains optimal function of glycoproteins to which drugs 
attach.4 Drug absorption through the nasal mucosa is also 
dependent on lipophilicity, drug ionization, and mucociliary 
clearance.6 These features make the nasal route a potentially 
useful route for the administration of drugs such as lipophilic 
opioids. The route avoids first-pass metabolism.4 The intrana-
sal route of drug administration has been used for a variety of 
drugs, such as vaccines,7 opioids, benzodiazepines, migraine 
therapies,8 and gene therapy.5 Metabolic enzymes are present 
in the nasal mucosa and thus are able to metabolize drugs 
administered there.5
Formulations
Typical formulations of intranasal fentanyl consist of using 
an intravenous solution either directly or via spray devices.9 
The ideal volume recommended is 0.15 mL in one or both 
nostrils.6 This is important, as run-off from the nasal cavity 
has the potential to be swallowed. Penetration enhancers have 
been used to overcome volume limitations, and additives 
such as polymers and gels or polysaccharides can enhance 
contact time, improving absorption.10 One study has demon-
strated improved fentanyl absorption with polysaccharides 
such as pectin, chitosan, and chitosan–poloxamer compared 
with transmucosal fentanyl.11 Biospheres may also increase 
residence time on the nasal mucosa.11
Intranasal pharmacokinetics 
compared with other routes  
of fentanyl administration
The pharmacology of several opioids has been evaluated 
after intranasal administration.6 Opioids that have been 
evaluated include the fentanyl series, oxycodone, methadone, 
buprenorphine, and diacetylmorphine. All the lipophilic 
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opioids show rapid absorption, with time to maximum 
plasma concentration (tmax) ranging from as short as 
9 minutes for alfentanyl to up to 30 minutes for sufentanil. 
When administered via an intranasal spray, all of the opioids 
described reach tmax in less than 30 minutes. Bioavailability 
of lipophilic opioids given intranasally is high and greater 
than the oral route for all step 3 opioids, with the exception of 
oxycodone.6 The pharmacokinetic data of all of the studies of 
opioids support the use of noninvasive intranasal drug delivery 
when a fast onset is indicated. When fentanyl is administered 
by the intranasal route, the bioavailability is nearly 70%, with 
tmax reached in 5–16 minutes.12 Fentanyl levels show dose 
dependency when administered intranasally. The absorption 
of fentanyl can be influenced by pH, with greater absorption 
as the pH increases.13 Temperature can influence absorption, 
with greater permeation of fentanyl intranasally.14 The half-
life is up to 65 minutes when given by intranasal route. 
Pharmacokinetic comparisons have been made between 
intranasal fentanyl and other routes of administration, such 
as transmucosally administered fentanyl. Transmucosal 
fentanyl has a decreased bioavailability and area under the 
curve compared with intranasal fentanyl.15 The half-life of 
transmucosal fentanyl is longer than intranasal fentanyl.15 
Compared with intravenous fentanyl, the intranasal route has 
a slower onset of action. The half-life of the intravenous route 
is longer than that of the intranasal route.16
Adverse effects
When given intranasally, fentanyl can cause not only local 
effects specific to the intranasal route but also systemic adverse 
effects typical for opioids in general.6 The systemic effects 
of intranasally administered fentanyl can include dizziness, 
as well as sedation, nausea, and constipation. Local effects 
include nasal discomfort and irritation, the most common 
adverse effect with short-term use. There are fewer data on 
the long-term effects of intranasal opioid administration, but 
reports exist of epistaxis, pharyngitis, and sinus congestion. 
Respiratory depression does not occur more frequently with 
this route.6 Some indications are that polymer fentanyl combi-
nations may prevent a higher incidence of adverse effects.17
Drug interactions
Fentanyl is metabolized by the cytochrome P450 3A4 liver 
isoenzyme system, and potent inhibitors of this enzyme may 
produce increased or prolonged opioid side effects.18 The 
concomitant use of other central nervous system depressants 
may produce additional sedative effects.
Clinical trials
Intranasal fentanyl has been evaluated for cancer-related 
breakthrough pain and postoperative pain and has been 
compared with morphine in several painful clinical 
conditions. There have been some studies in the management 
of symptoms in the hospice setting.
Cancer-related breakthrough pain
Breakthrough pain associated with cancer is defined as a 
transitory exacerbation of pain experienced by a patient 
who has relatively stable and adequately controlled baseline 
pain.19 The use of a lipophilic opioid such as fentanyl has 
been shown to be effective when given by other routes such 
as the transmucosal route20 and in formulations such as a 
buccal tablet,21 due to the lipophilic nature of the drug and 
its rapid onset of action. The rapid onset of action of fen-
tanyl can match the rapid onset of action for most forms of 
breakthrough pain. The rapid onset of action by the intranasal 
route has been evaluated as another alternative route for the 
management of breakthrough pain.
Intranasal fentanyl and placebo
Intranasal fentanyl spray (INFS) at a dose range of 
50–200 µg was evaluated for cancer-related breakthrough 
pain and compared with placebo. One multicenter, blinded, 
crossover trial22 focused on adult cancer patients who 
experienced at least three episodes of severe breakthrough 
pain per week, and up to a maximum of four episodes per 
day lasting longer than 15 minutes. Patients had already 
been receiving strong opioids such as oral morphine, 
oxycodone, or hydromorphone with dosages ranging from 
60 mg to 500 mg per day, and transdermal fentanyl dosages 
ranging from 25 µg to 200 µg per hour. Patients were 
required to be at stable opioid dosing levels, with pain scores 
less than 4 on an 11-point numeric rating scale (NRS) for 
pain for entry into the trial. Because there is evidence 
that the breakthrough dose of fentanyl does not correlate 
with the amount of scheduled opioid, doses of intranasal 
fentanyl for breakthrough pain were individually titrated. 
A dose was considered successful if it could treat three 
of four episodes of breakthrough pain. Responses were 
measured by categorical scale (0 = poor; 1 = fair; 2 = good; 
3 = very good; and 4 = excellent). A successful dose had 
to get a score of 2 on the categorical scale 60 minutes after 
the breakthrough dose. There also had to be an absence of 
adverse effects to qualify for a successful breakthrough 
dose. Once the breakthrough dose was determined, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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randomization occurred to treatment sequences composed 
of two sets of four administrations (numbered 1–4 and 
5–8), with each set comprising three INFS administrations 
and one placebo administration. Patients were instructed to 
treat eight episodes of breakthrough pain (to a maximum 
of four episodes daily) using the order in which the spray 
bottles were numbered (1–8). Patients recorded their pain 
in a diary using the 11-point NRS at times 10, 20, 40, 
and 60 minutes after administration. The main endpoint 
was the difference in the pain score at 10 minutes after 
administration (pain intensity difference [PID]10), with 
secondary endpoints being the sum of the pain intensities 
from baseline to 60 minutes after administration, and the 
general impression of efficacy at 60 minutes, using the 
aforementioned categorical scale. Clinically important 
PID10 scores are a decrease in pain of more than 2 points. 
Mean response rates were calculated for drug or placebo in 
each patient as well as reduction in pain intensities by more 
than 33% and more than 50%, respectively. One-hundred 
and eleven patients were included in the study from an initial 
120 patients. The results favored the intranasal fentanyl, as 
the PID10 was twice as great as for placebo (P , 0.001). 
The overall response rate for INFS was 51%, with 20% of 
responses observed in the placebo arm. Adverse effects were 
observed in nearly 20% of patients, the most common being 
nausea (4.5%) and vertigo (1.8%).
Fentanyl pectin formulation
A multicenter, randomized, blinded, placebo-controlled 
study conducted by the Nasal Spray 043 Study Group23 
evaluated the efficacy of fentanyl pectin nasal spray 
(FPNS) for cancer breakthrough pain. One-hundred and 
fourteen cancer patients who were taking at least 60 mg 
of oral morphine or an equivalent opioid and who had 
one to four episodes of moderate to severe breakthrough 
pain were eligible for participation. Patients were titrated 
to the appropriate breakthrough dose (open label). Once a 
dose was identified, patients were randomized to receive 
10 bottles, seven of which contained the effective dose and 
three contained placebo in a randomly assigned sequence. 
Patients could take up to four doses daily with 4 hours 
separated between doses. If the pain was not controlled in 
30 minutes, or an episode of breakthrough pain occurred 
within the 4-hour period, patients could take their usual 
breakthrough medication. Pain relief was measured by NRS 
and categorical scale at baseline and at 5, 10, 15, 30, 45, and 
60 minutes after administration. Patients had to rate overall 
satisfaction. Electronic diaries recorded information on the 
breakthrough doses. Adverse effect assessment included 
categorical scoring for local nasal effects.
Primary efficacy was measured by outcomes such as 
pain intensity, pain intensity differences from baseline, 
sum of pain intensity differences, pain relief, and total 
pain relief. Patients also evaluated ease and convenience 
by categorical scales (0–3). Seventy-two percent identified 
a breakthrough dose. Six percent withdrew due to lack of 
efficacy, and 5% withdrew due to adverse effects. Baseline 
pain scores were comparable between placebo and study 
drug groups. Fentanyl was more effective in reducing 
pain intensity at all time points and had quicker onset of 
analgesic effects than placebo. One-third of FPNS-treated 
episodes had clinically meaningful reduction at 10 minutes 
(P = 0.01 vs placebo) and had an increase to 66% of   episodes 
at 30 minutes (P , 0.0001 vs placebo). There were more 
2-point pain reductions with FPNS at each time point after 
dosing (P , 0.01). In addition, the FPNS group has a greater 
number of 1- or 2-point reductions at each time point. There 
was less need for additional breakthrough medications with 
FPNS (P , 0.001). Patient acceptability was better for 
the FPNS group at 30 and 60 minutes than for the placebo 
group. FPNS was also superior in terms of time to relief than 
placebo at 30 and 60 minutes (P , 0.0001) for both times. 
Scores for reliability of pain relief were better for the FPNS 
group, as were acceptability after the last treated episode 
and ease of use of the spray formulation in terms of conve-
nience and satisfaction. Adverse effects were greater in the 
FPNS group. Systemic adverse effects consisted of vomiting 
(10.6%), nausea (8.8%), and dizziness (8.0%). Local effects 
consisted of epistaxis (4.4%) and nasopharyngitis (3.5%). 
Two deaths in the treatment group and one in the placebo 
group were believed to be unrelated to the drug.
Long-term safety of intranasal 
fentanyl
Portenoy et al24 assessed the safety aspects of fentanyl pectin 
for cancer-related breakthrough pain. Patients in the study 
had chronic cancer pain requiring at least 60 mg of oral 
morphine equivalent per day and had one to four attacks of 
breakthrough pain per day. Individual dose titration identi-
fied the appropriate breakthrough dose. Dose changes were 
performed as necessary to optimize comfort, but 90% did not 
require a dose change. After reviewing the adverse effects of 
42,000 episodes of breakthrough pain in 110 patients, 24% 
experienced adverse effects that were systemic in nature 
and characterized as mild. There were no significant local 
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Intranasal versus oral transmucosal 
fentanyl citrate
Mercadante et al25 conducted an open-label crossover 
trial comparing intranasal with oral transmucosal fentanyl 
  citrate (OFTC). Patients with cancer pain were screened 
for   breakthrough cancer pain and, if eligible, received a 
test dose of fentanyl 50 µg. Patients whose pain was opioid 
responsive were entered into the study and randomized to 
receive INFS or OFTC. In the study, individual titration was 
conducted to identify a dose that could successfully treat 
three of four episodes of breakthrough pain. There was then 
a final phase lasting approximately 2 weeks, during which 
the identified doses with each formulation were used and 
compared with each other for onset of meaningful pain 
relief, pain intensity, and use. With regard to the intranasal 
fentanyl, patients could receive a second dose of intranasal 
analgesic if there was no pain relief after 10 minutes. If the 
second dose did not help, rescue analgesics were allowed 
10 minutes after the second intranasal spray. More rescue 
analgesics were allowed at 45 and 60 minutes, depending 
on whether the   second intranasal dose was required. The 
primary   outcome was the (stopwatch) measured time to 
patient-reported meaningful pain relief for either the OFTC 
or intranasal route of administration. Pain intensity (NRS 
0–10) was also measured at time points 5, 10, 15, 20, 30, 
and 60 minutes after administration of INFS or OTFC. 
If a rescue dose was taken at 60 minutes, the preceding pain 
intensity value was carried forward. PID was measured at 
5-minute intervals for the first 30 minutes, and the sum of 
PID was calculated for the 0–15 minute and 0–60 minute 
intervals.
Categorical scales were used to describe ease of use. 
Treatment preferences were recorded after the patients 
completed both arms. The investigators calculated the 
relationship between doses required for breakthrough pain 
and scheduled analgesic doses. Finally, the proportion of 
patients with a greater than 33% and a greater than 50% 
reduction in pain intensity score was also calculated for each 
treatment at 5, 10, 15, 20, 30, and 60 minutes postdosing. 
One-hundred and thirty-nine patients were enrolled in the 
trial, but 53 did not complete the titration phase. Rates of 
withdrawal were the same between groups. A total of 577 
breakthrough pain episodes were treated with INFS, and 
577 episodes were treated with OFTC. Ninety-three percent 
of patients treated six breakthrough episodes with INFS, 
and 92% were treated with OFTC. Nearly equal numbers 
of patients were able to find effective doses of INFS and 
OFTC (85% and 87%, respectively). In the INFS group, 
75% needed doses of 100–200 µg, and 60% in the OFTC 
group needed 200–400 µg doses for adequate breakthrough 
coverage. The investigators found a weak association 
between the amount of INFS taken and the amount of OFTC 
used for breakthrough pain, in that patients requiring higher 
INFS doses also needed higher OFTC doses, and those 
requiring lower doses of INFS needed lower doses of OFTC. 
Results in respect of the primary endpoint showed that the 
median time to meaningful pain relief was 11 minutes for 
INFS and 16 minutes for OFTC. More patients in the INFS 
group experienced a faster onset of pain relief than the OFTC 
group (P , 0.001). PID at 10 and 30 minutes was greater for 
the INFS group than for the OFTC group (P , 0.001) and 
at other times, such as 5, 15, 20, and 60 minutes postdosing. 
It appeared that the PIDs were in favor of the INFS group for 
60 minutes postdosing (P , 0.001). Statistically significantly 
greater proportions of the INFS group achieved 33% and 
50% reductions in pain scores than the OFTC group. There 
was a general impression of favorability that was greater with 
the INFS group. Fifty-six percent of patients experienced at 
least one adverse effect. The main adverse effect occurring 
in each arm of the study at a frequency of more than 5% 
was nausea. Most adverse effects were considered mild. The 
severe adverse effects were few in number and consisted 
of a slightly greater number in the INFS group (severe 
nausea and vomiting). One patient developed nasal ulcers 
in the INFS group, and the INFS was discontinued with 
subsequent healing of the wounds. Patients preferred INFS 
over OFTC (P , 0.001) and also found INFS to be easier 
to use than OFTC.
Postoperative pain in adults  
using INFS versus weak opioids
Striebel et al26 evaluated the effects of intranasal fentanyl 
versus weak opioids as postoperative analgesic therapy in 
20 patients receiving orthopedic procedures in a pilot study. 
On the first postoperative day, patients who had a postopera-
tive pain score of 40 on a visual analog scale (VAS) were 
randomized to receive either intranasal fentanyl at 0.025 mg 
every 6 minutes for 4 hours or “standard ward therapy” 
  consisting of agents such as pethidine, tramadol, metamizole, 
codeine, and diclofenac as single agents or in combination, 
followed by the alternative regimen. Pain was measured every 
30 minutes by VAS, after randomization, up to 480 minutes. 
The results in both arms of the study showed effective pain 
control at 30 minutes, but, as time elapsed, pain levels were 
lower in the intranasal fentanyl arm. Patients also expressed 
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Intravenous fentanyl versus 
intranasal fentanyl
Patient-controlled analgesia (PCA) with intranasal fentanyl 
was compared with intravenous fentanyl in the postopera-
tive period in 48 patients undergoing surgery for abdominal, 
orthopedic, or thyroid surgery.27 Eligible patients had to 
have a pain score of at least 40 on the VAS. Randomization 
was to fentanyl 25 µg intranasally and fentanyl 17.5 µg 
intravenously, with lock-out intervals of 6 minutes.   Blinding 
was achieved by double-dummy design, whereby each patient 
had an intravenous PCA device and an intranasal PCA device. 
When in pain, the patient activated both routes and received 
either fentanyl or saline. Pain intensity was measured by NRS 
for the duration of the 240-minute study. In the intranasal 
group, the first reduction in pain score was 21 ± 11 minutes 
(range 15–45 minutes), and in the intravenous group was 
22 ± 16 minutes (range 15–90 minutes). Overall, there were 
no differences in overall pain intensity, and patient-rated 
intranasal analgesia was rated as “excellent” or “good”. 
Intranasal fentanyl was also compared with intravenous 
fentanyl for the management of acute and breakthrough pain 
in patients undergoing molar extractions.28 Patients were 
randomized to one of four doses (75, 100, 150, or 200 µg) of 
  fentanyl by both intranasal and intravenous routes randomly 
after two separate extractions at 1 or more weeks apart, with 
pain scores on an NRS measured before   administration 
and at 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 
240 minutes. Patients indicated time to meaningful pain 
relief and duration of analgesia. Plasma fentanyl levels were 
assessed before and at 1, 3, 5, 7, 9, 12, 15, 25, 40, 60, 90, 120, 
and 180 minutes after administration. Twenty-four patients 
were enrolled. Tmax was delayed compared with intravenous 
dosing (12.8 and 6.0 minutes [P , 0.001]), and onset of anal-
gesia was slower for intranasal analgesia (7 and 2 minutes 
[P , 0.001]), but duration of analgesia did not differ between 
groups. There was a relationship between duration of effect 
and intranasal dose, and there was less use of breakthrough 
analgesia after the intranasal fentanyl (P , 0.005). Both 
groups tolerated the therapies well.
Pediatric analgesia
Intranasal fentanyl was compared with intravenous fen-
tanyl in pediatric patients after abdominal surgery.29 
  Postoperatively, 36 patients with pain scores greater than 6 
according to an objective pain scale (OPS) were randomized 
into one of two groups. Group A (n = 17) received 0.5 mg/kg 
of intranasal fentanyl, followed by an intravenous injection of 
sodium chloride (1 mL of 0.9%). Patients in group B (n = 19) 
received intranasal normal saline (1 mL of 0.9%), followed by 
intravenous fentanyl 0.5 µg/kg. Pain scoring was   conducted 
5 minutes later, and those with scores of 2 or higher received 
the same protocol once, with scoring conducted every 
1 minute. This was repeated 5 minutes later if scores were 
2 or higher once again. The goal of such titration was to get 
to an OPS score of 2 or lower. Sixty minutes after the first 
administration, the primary scheme was carried out once per 
hour until 24 hours later. There were no differences between 
groups in time to achieve a score of less than 2. There was a 
greater amount of fentanyl used in group A. There were more 
adverse effects consisting of dizziness (32%) and nausea 
(21%) in group B than in group A (12% dizziness and 32% 
nausea [P , 0.05]). Pain scores were equally reduced in both 
groups at 4 hours postadministration.
Other surgery and pediatrics
INFS has been used for analgesia in pediatric patients 
undergoing myringotomy.30 When given in conjunction 
with anesthesia, there is less postoperative agitation31 and 
analgesia that is equivalent in potency to other modalities 
such as nerve block.32
Intranasal fentanyl versus morphine
Several studies have been carried out comparing intranasal 
fentanyl with morphine. An emergency room-based, 
prospective, randomized, blinded, placebo-controlled study33 
was carried out to evaluate the efficacy of intravenous 
morphine, intranasal placebo, and intranasal fentanyl 
for long bone fractures. Sixty-seven children were 
randomized to intravenous morphine (10 mg/mL) and 
intranasal placebo or intranasal fentanyl (150 µg/mL) and 
intravenous placebo. Pain scores by VAS were measured at 
0, 5, 10, 20, and 30 minutes with adverse effects recorded. 
Thirty-four children received intravenous morphine and 
33 received intranasal fentanyl. There were no differences 
in pain intensity reduction between the groups (P = 0.333) 
at 5 minutes and at time intervals thereafter. The mean 
dose of INFS was 1.7 µg/kg and the mean morphine dose 
was 0.11 mg/kg. Another comparison with morphine 
was conducted in burn patients where 26 adult patients 
(22 males) with burn surface areas ranging from 1% to 25% 
were randomized to a placebo-controlled, crossover study 
over two periods and two treatments.34 Patients requiring 
identical wound management on consecutive days were 
randomized to patient-controlled intranasal fentanyl with oral 
placebo or oral morphine with intranasal placebo on the first 
day, with the alternating sequence on the subsequent day. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Patients reported their pain intensity on an NRS before, 
during, and after the procedure. The mean dose of intranasal 
fentanyl given was 1.48 ± 0.57 µg/kg and 0.35 ± 0.12 mg/kg 
of oral morphine. There were no differences in pain scores 
between the groups. Two patients in the oral morphine 
group experienced hypotension, but there was no respiratory 
depression. Three patients required rescue analgesia, two 
cases involving morphine and one involving fentanyl.
Other uses
Hospice
The hospice setting may be a place where intranasal routes 
of administration can have benefit. Twelve hospice patients35 
were evaluated for the analgesic effects of 20 µg of fentanyl 
for cancer-related breakthrough pain. Pain was rated by 
VAS before and 3, 5, 10, 15, 30, 45, and 60 minutes after 
receiving the dose. Eight of 12 experienced a reduction 
in pain score, four achieved an analgesic response after 
5 minutes, and seven achieved an analgesic response within 
10 minutes of receiving the dose. Nine patients felt that 
the analgesia obtained with the intranasal formulation was 
“good” or “very good”. Two patients experienced local nasal 
itching or discomfort on first use, but this disappeared with 
time. Of the three patients who did not experience a good 
response with the intranasal fentanyl, one had a fracture and 
two had what was described as “relatively higher baseline 
opioid doses”. A series of cases has shown efficacy for the 
use of intranasal fentanyl for the management of dyspnea 
in hospice patients.36 The cases were notable because the 
intranasal fentanyl was administered by nasal spray and had 
a rapid onset on action, usually within 1 minute, with good 
relief obtained in 1–4 minutes. There was no worsening of 
pulmonary function during administration of the intranasal 
fentanyl with any of the cases. Individual titration of the 
appropriate dose for dyspnea is necessary.
Methods of administration
Fentanyl doses have been administered in one or both nos-
trils using fentanyl solutions of 0.5, 1.0, and 2.0 mg/mL, 
corresponding to doses of 50, 100, and 200 µg of fentanyl.15 
The clinical trials for breakthrough pain suggest the use of 
nasal spray devices, which can provide more uniform dosing 
with patients.
Conclusion
The intranasal route of opioid administration shows 
great promise as an alternative to the traditional routes of 
administration. It appears to be especially compatible with 
highly lipophilic agents such as fentanyl. Overall, the use of 
the intranasal route appears to be of low burden to patients, 
is amenable for pain management for a variety of analgesic 
issues ranging from postoperative pain to cancer-related 
breakthrough pain, and is applicable to both adult and 
  pediatric patient populations. In all likelihood, the intranasal 
route of opioid administration will replace the oral route as 
an option for several types of breakthrough pain.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Patt RB, Burton AW. Pain associated with advanced malignancy, 
including adjuvant analgesic drugs in cancer pain management. 
  Evaluation and Treatment of Chronic Pain. New York: Lippincott, 
Williams & Wilkins; 1998:337–376.
  2.  Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic 
  non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 
112:372–380.
  3.  Dosen-Micovic L, Ivanovic M, Micovic V . Steric interactions and the 
activity of fentanyl analogs at the [mu]-opioid receptor. Bioorg Med 
Chem. 2006;14:2887–2895.
  4.  Shelley K, Paech MJ. The clinical applications of intranasal opioids. 
Curr Drug Deliv. 2008;5:55.
  5.  Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery 
for brain targeting. Curr Drug Deliv. 2005;2:165–175.
  6.  Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids 
for pain management in adults. Acta Anaesthesiol Scand. 2002; 
46:759–770.
  7.  Birkhoff M, Leitz M, Marx D. Advantages of intranasal vaccination and 
considerations on device selection. Indian J Pharm Sci. 2009;71:729.
  8.  Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al.   
A review of the clinical pharmacokinetics of opioids, benzodiazepines, 
and antimigraine drugs delivered intranasally. Clin Ther. 2009; 
31:2954–2987.
  9.  Schwagmeier  R,  Oelmann  T,  Dannappel  T,  Striebel  HW. 
  Patientenakzeptanz gegennber der patientenkontrollierten intrana-
salen Analgesie (PCINA). Der Anaesthesist. 1996;45:231–234.
  10.  Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG. The influence of 
solution viscosity on nasal spray deposition and clearance. Int J Pharm. 
1988;43:221–224.
  11.  Illum L, Jorgensen H, Bisgaard H, et al. Bioadhesive microspheres as a 
potential nasal drug delivery system. Int J Pharm. 1987;39:189–199.
  12.  Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. Phar-
macokinetics, analgesic effect, and tolerability of a single   preprocedural 
dose of intranasal fentanyl in patients undergoing drain removal after 
breast reduction or augmentation surgery: a prospective, randomized, dou-
ble-blind, placebo-controlled study. Clin Ther. 2010; 32:1427–1436.
  13.  Paech MJ, Lim CB, Banks SL, et al. A new formulation of nasal 
fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia. 
2003;58:740–744.
  14.  Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for 
the management of pain. Drugs. 2010;70:57–72.
  15.  Panagiotou I, Mystakidou K. Intranasal fentanyl: from pharmaco-
kinetics and bioavailability to current treatment applications. Expert 
Rev Anticancer Ther. 2010;10:1009–1021.
  16.  Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, 
efficacy, and tolerability of fentanyl following intranasal versus 
intravenous administration in adults undergoing third-molar extraction:   
a randomized, double-blind, double-dummy, two-way, crossover study. 
Clin Ther. 2008;30:469–481.Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
164
Prommer and Thompson
  17.  Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons 
of three nasal fentanyl formulations; pectin, chitosan and chitosan-
poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138.
  18.  Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 
2009;12:947–954.
  19.  Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence 
and characteristics. Pain. 1990;41:273–281.
  20.  Coluzzi PH, Schwartzberg L. Breakthrough cancer pain: a randomized 
trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine 
sulfate immediate release (MSIR). Pain. 2001;91:123–130.
  21.  Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, 
placebo-controlled study of fentanyl buccal tablet for breakthrough 
pain in opioid-treated patients with cancer. Clin J Pain. 2006; 
22:805.
  22.  Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability 
of intranasal fentanyl spray 50 to 200 [mu] g for breakthrough pain in 
patients with cancer: a phase III, multinational, randomized, double-
blind, placebo-controlled, crossover trial with a 10-month, open-label 
extension treatment period. Clin Ther. 2009;31:1177–1191.
  23.  Taylor D, Galan V , Weinstein SM, et al. Fentanyl pectin nasal spray 
in breakthrough cancer pain. J Support Oncol. 2010;8:184.
  24.  Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, 
  tolerability, and consistency of effect of fentanyl pectin nasal spray for 
breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag. 
2010;6:319.
  25.  Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal 
fentanyl spray with oral transmucosal fentanyl citrate for the treatment 
of breakthrough cancer pain: an open-label, randomised, crossover trial. 
Curr Med Res Opin. 2009;25:2805–2815.
  26.  Striebel HW, Olmann T, Spies C, Brummer G. Patient-controlled 
intranasal analgesia (PCINA) for the management of postoperative 
pain: a pilot study. J Clin Anesth. 1996;8:4–8.
  27.  Toussaint S, Maidl J, Schwagmeier R, Striebel HW. Patient-controlled 
intranasal analgesia: effective alternative to intravenous PCA for 
  postoperative pain relief. Can J Anaesth. 2000;47:299–302.
  28.  Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, 
and tolerability of fentanyl following intranasal versus   intravenous 
administration in adults undergoing third-molar extraction:   
a   randomized, double-blind, double-dummy, two-way, crossover study. 
Clin Ther. 2008;30:469–481.
  29.  Cheng X, Li JH. Effects of fentanyl administrated nasally and intrave-
nously in post-operative analgesia in pediatric children: a comparative 
study of 36 cases. Zhonghua Yi Xue Za Zhi. 2008;88:2898.
  30.  Galinkin JL, Fazi LM, Cuy RM, et al. Use of intranasal fentanyl in 
children undergoing myringotomy and tube placement during halothane 
and sevoflurane anesthesia. Anesthesiology. 2000;93:1378.
  31.  Finkel JC, Cohen IT, Hannallah RS, et al. The effect of intranasal 
  fentanyl on the emergence characteristics after sevoflurane anesthesia in 
children undergoing surgery for bilateral myringotomy tube   placement. 
Anaesth Analg. 2001;92:1164.
  32.  Voronov P, Tobin MJ, Billings K, et al. Postoperative pain relief in 
infants undergoing myringotomy and tube placement: comparison of a 
novel regional anesthetic block to intranasal fentanylûa pilot analysis. 
Pediatric Anesthesia. 2008;18:1196–1201.
  33.  Borland M, Jacobs I, King B, O’Brien D. A randomized controlled trial 
comparing intranasal fentanyl to intravenous morphine for managing 
acute pain in children in the emergency department. Ann Emerg Med. 
2007;49:335–340.
  34.  Borland ML, Bergesio R, Pascoe EM, et al. Intranasal fentanyl is an 
equivalent analgesic to oral morphine in paediatric burns patients for 
dressing changes: a randomised double blind crossover study. Burns. 
2005;31:831–837.
  35.  Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics 
of breakthrough pain in cancer patients admitted to a hospice. J Pain 
Symptom Manage. 2000;20:87–92.
  36.  Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. 
J Pain Symptom Manage. 2008;36:e3.